Sitagliptin increased intact GLP-1 and GIP through DPP-4 inhibition, but reduced total GLP-1 and GIP (feedback inhibition) without affecting the numerical contribution of the incretin effect. Insulin secretion with sitagliptin treatment was similarly stimulated with both oral and “isoglycemic” intravenous glucose (Diabetes)